News
Allan Bradley on the company and its vision
Our CEO Allan Bradley shares an overview of T-Therapeutics, our technology and how the team is seeking to reshape the clinical landscape for cancer patients.
Read More
Phoebe Lee on day-to-day life at T-Therapeutics
Phoebe Lee, a scientist in our Pipeline Expression team, gives a flavour of T-Therapeutics as a workplace, as well as the broader Cambridge life sciences ecosystem.
Read More
Camillo Moschner on integrating biology and engineering
Camillo Moschner, PhD, a scientist in our Synthetic Biology & Automation department, talks about the importance of bringing biology and engineering closer together.
Read More
Amy Li on the OpTiMus platform
Amy Li, Director for Drug Discovery at T-Therapeutics, outlines how discoveries from the antibody field have informed the OpTiMus® platform and engineering of humanised TCRs.
Read More
Michael Casey on being at the cutting edge of the soluble TCR field
Michael Casey, Principal Data Scientist, outlines how T-Therapeutics is building a soluble TCR ‘factory’ to reliably develop new medications for a range of indications.
Read More
Ying Ying (Joyce) Tan on how she joined T-Therapeutics and the company culture
What’s it like moving from academia to a lab role at a growing biotech? Ying Ying (Joyce) Tan, a scientist on the Target Discovery team, gives her perspective on the culture of collaboration at T-Therapeutics.
Read More
Ruben Cabanillas on T-Therapeutics’ patient-focussed approach
Ruben Cabanillas, Senior Director of Translational Medicine, discusses the importance of keeping the patient at the front of mind at every stage of research and development.
Read More
Allan Bradley on the importance of the team
T-Therapeutics’ CEO Allan Bradley shares his thoughts on why a diverse, expert team with a shared vision is so vital to the future success of the business.
Read More
OpTiMus: A Novel Transgenic Mouse Platform for Discovery of Fully Human Therapeutic-Grade TCRs and Generation of Bispecific T Cell Engagers
This presentation has been presented at: 5th Annual TCR-Based Therapies for Solid Tumours Summit, Boston on 24th March 2024 by E-Chiang Lee (Ex VP Research) Immuno-Oncology Summit, Europe on 25th March 2024 by Wei Wang (Snr Director of Technology)
Read More
David Hung Joins T-Therapeutics
Dr David Hung has joined T-Therapeutics as Chairman of its Board of Directors. In this video, which accompanied the announcement, Dr Hung explains his decision: “I have always wanted to be on the cutting-edge of science and transform the practice of medicine. I…
Read More
T-Therapeutics appoints Dr David Hung as Chairman
Industry veteran, founder of Medivation and serial entrepreneur joins T-Therapeutics to support development of the company’s pipeline of TCR-based immuno-oncology drugs 12 June 2024; Cambridge, England – T-Therapeutics, a biotechnology company developing next-generation soluble TCR therapeutics targeting cancer and autoimmune indications, today announces…
Read More
T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment
Fundraise led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital with participation from Sanofi Ventures and the University of Cambridge Venture Fund Unique transgenic mouse platform harnesses natural power of T cells to build a portfolio of first-in-class cancer medicines…
Read More
